Kingdon Capital Management, L.L.C. Relmada Therapeutics, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $639 Million
- Q2 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 200,000 shares of RLMD stock, worth $334,000. This represents 0.95% of its overall portfolio holdings.
Number of Shares
200,000Holding current value
$334,000% of portfolio
0.95%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
55Shares Held
5.43MCall Options Held
0Put Options Held
0-
Driehaus Capital Management LLC Chicago, IL740KShares$1.24 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA619KShares$1.03 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$957,4340.0% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD397KShares$662,1780.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$608,0080.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $47.8M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...